Press Release
00/CMX/83
30th November 2000
 

Real time environmental microbial monitoring for the pharmaceutical industry
Chemunex announces new application development for ChemScan RDI

 

The ChemScan RDI microbial analyser from Chemunex is being extended to real time environmental monitoring of air, and later to personnel and surfaces, as announced at the recent annual Parenteral Drug Association meeting in Basle, Switzerland.

The addition of environmental monitoring to the already well established ChemScan RDI water testing methods will, for the first time, provide the pharmaceutical industry with a unique capability to implement real time monitoring of all critical areas subject to risk of microbial contamination. This will allow companies to minimise risks before manufacturing products and to detect contamination early enough to minimise subsequent losses and plant downtime.

Current environmental monitoring procedures use traditional plate culture, which provides results only after several days and therefore prevents any proactive monitoring. The ChemScan RDI microbial analyser, produces sensitive results down to a single micro-organism within 90 minutes for filterable products. The extension of ChemScan RDI's capabilities to the this critical process control step means that manufacturers will be able to control all areas for potential microbial contamination using a single analytical platform with enhanced detection sensitivity and very short response time.

Chemunex R&D developed a unique approach to overcome the challenge of collecting micro-organisms from the environment and transferring them on to ChemScan RDI for analysis without damaging their viability. The technology developed, for which a patent protection has been filed, uses a water-soluble polymer which, in its solid form, collects the micro-organisms and is subsequently solubilised prior to analysis on ChemScan RDI. This new development, which was originally started in collaboration with British scientists, is supported by leading pharmaceutical companies, such as Glaxo Wellcome, SmithKline Beecham, Astra Zeneca.

Environmental monitoring represents a critical process control step in the manufacture of pharmaceutical products, especially those manufactured within highly controlled clean room conditions. The test includes monitoring of air, personnel and surfaces and, to meet regulatory authority requirements, must be capable of detecting one single micro-organism. As it represents around one third of the number of microbial tests performed in an average production plant, the volume of environmental testing is high.

 
- ends -
 

Issued on behalf of Chemunex by HCC.DeFacto Group plc
For more information please contact:

Dr Sarah Perceval HCC•De Facto (UK) +44 (0) 20 7496 3300
Dr Mike Brailsford Chemunex (France) +33 (0) 149 59 20 00

Return to Index

Contact Us News & Events Literature Library Products Company Profile Home